Zamani Batol, Farshbaf Shima, Golkar Hamid R, Bahmani Fereshteh, Asemi Zatollah
1Department of Gastroenterology,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.
2Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,Kashan PO Box 8715988141,Iran.
Br J Nutr. 2017 Apr;117(8):1095-1102. doi: 10.1017/S000711451700085X. Epub 2017 May 11.
Synbiotic intake may be associated with reduced inflammation in patients with rheumatoid arthritis (RA) due to optimised inflammatory markers, oxidative stress and insulin resistance. This research was conducted to assess the effects of synbiotic supplementation on the clinical and metabolic parameters of patients with RA. A total of fifty-four patients with RA were allocated into two groups to receive either a synbiotic capsule (n 27) or a placebo (n 27) for 8 weeks in this randomised, double-blind, placebo-controlled trial. Fasting blood samples were taken at baseline and week 8 of the study to quantify related markers. After the 8-week intervention, compared with the placebo, synbiotic supplementation resulted in a significant reduction in serum high-sensitivity C-reactive protein (hs-CRP) levels (-1427·8 (sd 3267·2) v. +2833·4 (sd 5639·7) ng/ml, P=0·001). In addition, compared with the placebo, synbiotic supplementation improved disease activity score-28 joints (DAS-28) (-1·6 (sd 0·8) v. -0·3 (sd 0·5), P<0·001) and visual analogue scales (VAS) pain (-30·4 (sd 18·7) v. -11·5 (sd 15·9), P<0·001). In addition, a significant elevation in plasma nitric oxide (NO) (+0·8 (sd 4·4) v. -2·6 (sd 4·5) µmol/l, P=0·008), and significant reductions in insulin values (-13·8 (sd 26·4) v. +4·2 (sd 28·2) pmol/l, P=0·01), homoeostasis model of assessment-estimated insulin resistance (HOMA-IR) (-0·5 (sd 1·0) v.+0·1 (sd 1·1), P=0·03) and homoeostatic model assessment-β-cell function (HOMA-B) (-9·4 (sd 17·9) v. +3·3 (sd 18·9), P=0·01) following supplementation with the synbiotic compared with the placebo. Compared with the placebo, synbiotic supplementation also resulted in a significant increase in plasma GSH (+36·6 (sd 63·5) v. -58·5 (sd 154·4) µmol/l, P=0·005). Overall, our study demonstrated that synbiotic supplementation for 8 weeks among patients with RA had beneficial effects on hs-CRP, DAS-28, VAS, NO, insulin levels, HOMA-IR, HOMA-B and GSH levels.
由于炎症标志物、氧化应激和胰岛素抵抗得到优化，摄入合生制剂可能与类风湿关节炎（RA）患者炎症减轻有关。本研究旨在评估补充合生制剂对RA患者临床和代谢参数的影响。在这项随机、双盲、安慰剂对照试验中，共有54例RA患者被分为两组，分别接受合生制剂胶囊（n = 27）或安慰剂（n = 27）治疗8周。在研究基线和第8周采集空腹血样以量化相关标志物。8周干预后，与安慰剂组相比，补充合生制剂使血清高敏C反应蛋白（hs-CRP）水平显著降低（-1427.8（标准差3267.2）对+2833.4（标准差5639.7）ng/ml，P = 0.001）。此外，与安慰剂组相比，补充合生制剂改善了疾病活动评分28关节（DAS-28）（-1.6（标准差0.8）对-0.3（标准差0.5），P<0.001）和视觉模拟评分（VAS）疼痛（-30.4（标准差18.7）对-11.5（标准差15.9），P<0.001）。此外，与安慰剂组相比，补充合生制剂后血浆一氧化氮（NO）显著升高（+0.8（标准差4.4）对-2.6（标准差4.5）µmol/l，P = 0.008），胰岛素值显著降低（-13.8（标准差26.4）对+4.2（标准差28.2）pmol/l，P = 0.01），稳态模型评估估计的胰岛素抵抗（HOMA-IR）（-0.5（标准差1.0）对+0.1（标准差1.1），P = 0.03）和稳态模型评估β细胞功能（HOMA-B）（-9.4（标准差17.9）对+3.3（标准差18.9），P = 0.01）。与安慰剂组相比，补充合生制剂还使血浆谷胱甘肽（GSH）显著增加（+36.6（标准差63.5）对-58.5（标准差154.4）µmol/l，P = 0.005）。总体而言，我们的研究表明，RA患者补充合生制剂8周对hs-CRP、DAS-28、VAS、NO、胰岛素水平、HOMA-IR、HOMA-B和GSH水平有有益影响。
